Study of Triostat in Infants During Heart Surgery

Completed · Phase 3 · Has a placebo group

Conditions studied: Heart Defects, Congenital

In brief

This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery.

Key facts

Study ID

NCT00027417

Run by

Michael Portman

People needed

195

Starts

2001-04-01

Expected to finish

2007-08-01

Last updated by the study team

2013-08-05

Who can join

Age: any, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of one of the following:
• Ventricular septal defect (VSD)
• Infant coarctation of the aorta
• Transposition of the great arteries
• Tetralogy of Fallot
• Complete atrioventricular canal defect
• Hypoplastic left heart, including patients who undergo a Norwood type procedure for aortic or mitral atresia
• Patient must be scheduled for surgery.

You may not qualify if…

• Certain additional defects and/or requirement for additional surgery.

Where it is running

• Children's Hospital and Regional Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.